MedTrace Logo

SUROVA - Surgery in Ovarian Cancer, Comparing Primary and Interval Cytoreductive Surgery

NCT06223763 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 5000

Last updated 2024-01-25

No results posted yet for this study

Summary

An international worldwide retrospective cohort observational study comparing primary cytoreductive surgery with neoadjuvant chemotherapy and interval cytoreductive surgery in patients with carcinoma of the ovary, fallopian tubes, and peritoneum.

Conditions

  • Epithelial Ovarian Cancer
  • Fallopian Tube Neoplasms
  • Peritoneal Neoplasms

Interventions

PROCEDURE

Cytoreductive surgery

Cytoreductive surgery is a surgical procedure performed with the goal of reducing the tumor burden in the body. This type of surgery is commonly used in the treatment of certain types of cancers, especially in the context of peritoneal carcinomatosis. During cytoreductive surgery, the surgeon attempts to remove as much visible tumor as possible. This may involve the removal of tumors from specific organs and the elimination of tumor lesions on the surface of intra-abdominal organs.

DRUG

Neoadjuvant chemotherapy

Neoadjuvant chemotherapy refers to chemotherapy administered before the primary treatment in cancer management. The goals include reducing tumor size, treating micrometastases, assessing treatment response, converting inoperable tumors to operable ones, and preserving organs or tissues.

DRUG

Adjuvant chemotherapy

Adjuvant chemotherapy is chemotherapy given after the primary treatment, such as surgery or radiation therapy, with the aim of eliminating any remaining cancer cells and reducing the risk of recurrence. It is administered to patients who have undergone the initial treatment to enhance the overall effectiveness of the therapy.

Sponsors & Collaborators

  • Asociación de Amigos de la Universidad de Navarra

    collaborator UNKNOWN

  • Clinica Universidad de Navarra, Universidad de Navarra

    lead OTHER

Principal Investigators

  • Luis M Chiva, MD, PhD · University of Navarra

  • Pilar Ordás, PhD student · University of Navarra

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-01
Primary Completion
2024-06-01
Completion
2024-06-01

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06223763 on ClinicalTrials.gov